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Introduction: Nutritional support in patients with cancer aims at improving quality of 51 
life. Whether use of nutritional support is also effective in improving clinical outcomes 52 
remains understudied. 53 
Methods: In this preplanned secondary analysis of patients with cancer included in a 54 
prospective, randomized-controlled, Swiss, multicenter trial (EFFORT), we compared 55 
protocol-guided individualized nutritional support (intervention group) to standard 56 
hospital food (control group) regarding mortality at 30-day (primary endpoint) and 57 
other clinical outcomes.  58 
Results: We analyzed 506 patients with a main admission diagnosis of cancer, 59 
including lung cancer (n=113), gastrointestinal tumors (n=84), hematological 60 
malignancies (n=108) and other types of cancer (n=201). Nutritional risk based on 61 
Nutritional Risk Screening [NRS 2002] was an independent predictor for mortality 62 
over 180 days with a (age-, sex-, center-, type of cancer-, tumor activity- and 63 
treatment-) adjusted hazard ratio of 1.29 (95% CI 1.09 to 1.54; p=0.004) per point 64 
increase in NRS. In the 30-day follow-up period, 50 patients (19.9%) died in the 65 
control group compared to 36 (14.1%) in the intervention group resulting in an 66 
adjusted odds ratio of 0.57 (95% CI 0.35 to 0.94; p=0.027). Interaction tests did not 67 
show significant differences in mortality across the cancer type subgroups. Nutritional 68 
support also significantly improved functional outcomes and quality of life measures. 69 
Conclusion: Compared to usual hospital nutrition without nutrition support, 70 
individualized nutritional support reduced the risk for mortality and improved 71 
functional and quality of life outcomes in cancer patients with increased nutritional 72 
risk. These data further support the inclusion of nutritional care in cancer 73 
management guidelines. 74 













 Nutritional risk in patients with cancer was an independent prognostic indicator 78 
regarding 6-month mortality 79 
 In patients with cancer and increased nutritional risk, individualized nutritional 80 
support during the hospital stay reduced mortality 81 
 Nutritional support also improved functional and quality of life outcomes.  82 
 83 












Effective anti-cancer strategies are based on combination of disease-modifying 86 
therapies and supportive and palliative care. The goal of supportive and palliative 87 
care is to address needs of patients with cancer and thus enhance quality of life.[1] 88 
Early and simultaneous delivery of disease-modifying therapy and palliative care has 89 
been demonstrated to improve clinical outcomes. However, the specific role of 90 
nutritional care in favoring a better outcome in patients with cancer remains 91 
understudied. 92 
Malnutrition affects about 30% of oncological and hematological malignancy patients 93 
and is associated with higher mortality, impaired functional status and longer hospital 94 
stays.[2-4] The clinical presentation of malnutrition in patients with cancer may vary 95 
from loss of appetite and/or weight, to loss of muscle mass with sarcopenia, to 96 
severe tumor cachexia. [5] Several factors put patients with cancer at high 97 
malnutrition risk including tumor-derived cytokine release causing loss of appetite 98 
and anorexia, and side effects of cancer treatment again interfering with appetite and 99 
normal food intake.[6-8] In addition, once admitted to the hospital, patients with 100 
cancer are at high risk for further deterioration of the nutritional status due to fasting 101 
for diagnostic studies, treatment side effects and overall suboptimal nutritional 102 
management.  103 
To prevent adverse clinical outcomes associated with malnutrition, the European 104 
Society for Clinical Nutrition and Metabolism (ESPEN) recommends identifying 105 
cancer patients at nutritional risk through early screening, followed by nutritional 106 
counseling and nutritional support.[6, 7] Different screening tools are recommended 107 
for this purpose, including the Nutritional Risk Screening (NRS 2002).[9] [10, 11] 108 
However, there is relatively little evidence regarding this recommendation for the 109 











somewhat inconclusive.[5, 12] While some trials looking at patients with colorectal 111 
cancer found improved outcomes associated with nutritional support 112 
interventions,[13, 14]  other trials have not provided evidence that in favor of using 113 
nutritional interventions.[12] Whether malnutrition is indeed a modifiable risk factor 114 
and improved by nutritional interventions has therefore been questioned. 115 
Herein, we performed a preplanned secondary analysis of a randomised multicentre 116 
trial in Switzerland [4, 15], investigating the effect of nutritional support during the 117 
hospital stay compared to usual care hospital food on mortality and other clinical 118 
outcomes in patients with different types of cancer.  119 
 120 
Methods 121 
Study design  122 
This is a secondary analysis of the subset of patients with cancer as a main 123 
admission diagnosis included in the EFFORT (Effect of early nutritional support on 124 
Frailty, Functional Outcomes and Recovery of malnourished medical inpatients) 125 
trial.[4] Effort was an investigator-initiated, open-label, randomized, controlled trial in 126 
eight Swiss hospitals investigating the effect of early individual nutritional support on 127 
medical outcomes in patients at risk of malnutrition. The trial protocol and the results 128 
of the main trial, as well as secondary outcomes, have been published previously.[4, 129 
11, 16-22] The Ethics Committee of Northwest and Central Switzerland (EKNZ) 130 
approved the study protocol in January 2014 (EKNZ; 2014_001). 131 
 132 
Patient population 133 
All participating centers had an active malnutrition screening in place using the NRS 134 
2002. This score is a well-established tool for assessing malnutrition risk based on a 135 











points.[9, 11] A score of 3 points or more indicates increased nutritional risk. For the 137 
purpose of this study, we stratified the nutritional risk of patients based on NRS (i.e., 138 
moderate, high and very high risk defined as NRS 3, 4 and ≥5 points). 139 
For the initial trial, we enrolled adult patients with a NRS total score ≥3 points and an 140 
expected length of hospital stay of >4 days. Exclusion criteria were initial admission 141 
to intensive care units or surgical units; patients with terminal illness; admission 142 
diagnosis of anorexia nervosa, acute pancreatitis, acute liver failure, cystic fibrosis or 143 
stem-cell transplantation and history of gastric bypass surgery. Also, patients unable 144 
to ingest food orally, already receiving nutritional support or existing contraindications 145 
for nutritional support, and those previously included in the study were excluded. All 146 
patients eligible for this secondary analysis had a documented main admission 147 
diagnosis of cancer, which was confirmed and validated by a complete chart review 148 
after hospital discharge. The reporting of the proportion of patients with cancer thus 149 
differs from the original trial where diagnosis was based on admission data only. We 150 
also classified patients based on the type of cancer based on a complete review of 151 
the medical records. Tumor activity was defined as “active” if patients received 152 
antitumor treatment in the previous year or if the first diagnosis of cancer was made 153 
on admission. We also included “non-active” patients with cancer in the analysis if 154 
above mentioned definition was not met, but cancer was a main admission diagnosis.  155 
 156 
Procedures 157 
After trial inclusion, we randomized patients by use of an interactive web system 1:1 158 
to the intervention group receiving individualised nutritional support according to an 159 
implementation protocol[23], or the control group receiving usual hospital food 160 
without nutritional support. In the intervention group, nutritional support was initiated 161 











Patients received individualized nutritional support to reach protein and energy goals, 163 
defined for each patient upon hospital admission by a trained registered dietician. 164 
Energy requirements were predicted using the weight-adjusted Harris-Benedict 165 
equation.[24] Daily protein intake was set at 1.2–1.5 g/kg body weight to adjust for 166 
higher protein breakdown during acute disease[25], with lower targets for patients 167 
with acute renal failure (0.8 g per kg of body weight). To reach these goals, an 168 
individual nutritional plan was developed by a trained registered dietician for each 169 
patient. This plan was initially based on oral nutrition provided by the hospital kitchen 170 
(including food adjustment according to patient preferences, food fortification (e.g., 171 
enrichment of hospital food by adding protein powder) and providing patients with 172 
between-meal snacks) and oral nutritional supplements[26, 27]. A further increase in 173 
nutritional support to enteral tube feeding or parenteral feeding was recommended if 174 
at least 75% of energy and protein targets could not be reached through oral feeding 175 
within 5 days. Nutritional intake was reassessed every 24–48 h throughout the 176 
hospital stay by a trained registered dietician based on daily food records for each 177 
patient. Upon hospital discharge, patients received dietary counselling and, if 178 
indicated, a prescription for oral nutritional supplements in the outpatient setting. 179 
There was no planned follow-up regarding nutritional intake in the outpatient setting.  180 
Control group patients received standard hospital food according to their ability and 181 
desire to eat, with no nutritional consultation and no recommendation for additional 182 
nutritional support. 183 
 184 
Outcomes 185 
The primary endpoint was all-cause mortality within 30 days. The main secondary 186 
endpoints was adverse outcome, a composite endpoint predefined for the initial 187 











the medical ward, non-elective hospital readmission after discharge, and major 189 
complications including adjudicated nosocomial infection, respiratory failure, a major 190 
cardiovascular event (e.g., stroke, intracranial bleeding, cardiac arrest, myocardial 191 
infarction) or pulmonary embolism, acute renal failure, gastro-intestinal events 192 
(including hemorrhage, intestinal perforation, acute pancreatitis) or a decline in 193 
functional status of 10% or more from admission to day 30 measured by the Barthel’s 194 
index. A detailed description of outcomes is provided in the Appendix. 195 
Additional hospital outcomes included admission to intensive care, non-elective 196 
hospital readmission within 30 days and mean length of hospital stay and functional 197 
outcome such as a decline in functional status of 10% or more within 30 days, and 198 
functional impairment (measured by the Barthel’s Index and quality of life assessed 199 
with the European Quality of Life 5 Dimensions Index, including the EQ-5D VAS 200 
visual-analogue scale). Barthel’s scores range from 0 to 100, with higher scores 201 
indicating better performance of activities of daily living. The European Quality of Life 202 
5 Dimensions index (EQ-5D) ranges from 0 to 100, with higher scores indicating 203 
better quality of life. EQ-5D VAS (including visual-analogue scale) ranges from 0 to 204 
100, with higher scores indicating better health status.  205 
As an additional secondary outcome, we also assessed mortality after a follow-up 206 
time of 6 month, where we had information from 1995 of 2028 patients (98%) 207 
included in the initial trial.[17] 208 
 209 
Statistical analyses 210 
For this secondary analysis, we used a similar statistical approach as in the original 211 
trial[4, 16]. We tested the hypothesis that individualised nutritional support is superior 212 
to usual hospital food with regard to mortality and other secondary endpoints. We 213 











with a main admission diagnosis of cancer who had undergone randomisation unless 215 
they withdrew consent. Categorical variables are presented as counts (percentages) 216 
and continuous variables as means and standard deviations (SD).  217 
First, we investigated the prognostic implications of nutritional risk by calculation of 218 
regression analysis regarding NRS and clinical outcomes adjusted for important 219 
confounders (patient age, sex, study center, cancer subgroups, tumor activity and 220 
treatment). We calculated Cox regression models for time-to-event analyses with 221 
reporting of hazard ratios (HR) and illustrated the probability of all-cause mortality in 222 
Kaplan-Meier survival curves. We used logistic regression for binary data and linear 223 
regression for continuous outcomes. Second, we compared outcomes between 224 
randomization arms by means of regression analysis adjusted for study center, 225 
Barthel’s Index at admission and NRS at baseline (as predefined in our protocol).[15] 226 
We used logistic regression for all binary outcomes with reporting of odds ratios 227 
(ORs) and corresponding 95% confidence intervals (CI’s), and linear regression for 228 
continuous outcomes with reporting of coefficients (differences). Finally, we 229 
conducted subgroup analyses for patient age, sex, risk for malnutrition by NRS, 230 
cancer type subgroups, tumor activity and treatment, and reason for admission. We 231 
calculated interaction analysis to test for effect modification by main prognostic 232 
factors.  233 
All statistical analyses were performed using STATA 15.1 (Stata Corp, College 234 
Station, TX, USA). A P value <0.05 (for a 2-sided test) was considered to indicate 235 
statistical significance. 236 
 237 
Results 238 
This analysis includes 506 patients with a confirmed main diagnosis of cancer at 239 











(255 intervention group patients and 251 controls) from an original cohort of 2028 241 
EFFORT trial patients Supplemental Figure 1 shows the detailed patient flow. 242 
Overall, patients had different types of cancers and a high burden of comorbidities. 243 
The most frequent types of cancer were lung cancer (n=113), hematological 244 
malignancies (n=108) and gastrointestinal tumors (n=84). The most common reason 245 
for hospitalization was cancer treatment, new cancer diagnosis and failure to thrive 246 
associated with the cancer diagnosis. Detailed baseline characteristics are shown in 247 
Table 1 for both groups.  248 
Caloric and protein intake of patients during the in-hospital study period is listed in 249 
Appendix, Supplemental Table 1. Compared to control group patients, intervention 250 
group patients had a significantly higher mean caloric (1411 vs 1154 kcal/day) and 251 
protein (52.7 vs 44.2 g protein/day) intake during the index hospital stay. 252 
 253 
Association of nutritional risk with mortality and other endpoints  254 
Nutritional risk as measured using NRS 2002 was strongly associated with mortality 255 
over the 180-day follow-up with an adjusted HR of 1.37 (95% CI 1.15 to 1.61), 256 
p<0.001) per point increase in NRS. Figure 1 shows the time to death stratified by 257 
NRS with shorter time until death with higher NRS groups. We also observed an 258 
association between NRS and the composite endpoint of adverse outcomes 259 
(adjusted OR per point increase in NRS of 1.42 [95% CI 1.11 to 1.83]; p=0.006). 260 
Similar results were found for mean length of hospital stay, functional decline and 261 
impairment in quality of life (Table 2). 262 
 263 
Effect of nutritional support on clinical outcomes 264 
A total of 50 patients (19.9%) in the control group died within 30 days compared to 36 265 











0.94; p=0.027] (Table 3). These results were also illustrated in Kaplan Meier 267 
estimates stratified by randomization group (Figure 2). 268 
We also investigated effects of nutritional support regarding mortality over 6 months 269 
of follow-up. We recorded 128 (52.7%) deaths in the control group compared to 115 270 
death (47.3%) in the intervention group resulting in an adjusted HR of 0.83 (95%CI 271 
0.65 to 1.08, p=0.18) (see supplemental figure 3 in the Appendix).   272 
Compared to the intervention group, there was a higher risk in the control group for 273 
functional decline in activities of daily living (defined by Barthel scale) (adjusted OR 274 
0.59 [95% CI 0.38 to 0.93]; p=0.021). In addition, patients receiving nutritional 275 
support showed significant improvements in quality of life as defined by EQ-5D Index 276 
(adjusted coefficient 0.08 [95% CI 0.01 to 0.15]; p=0.016) and by EQ-5D VAS 277 
(adjusted coefficient 6.16 [95% CI 0.51 to 11.8]; p=0.033). No significant differences 278 
were found for other secondary outcomes including the composite outcome, length of 279 
hospital stay and non-elective hospital readmission (Table 3). 280 
 281 
Subgroup analysis for mortality and adverse outcome 282 
We also performed several pre-planned subgroup analyses to investigate whether 283 
effects of nutritional support were similar among patients with different 284 
sociodemographic characteristics, different types of cancers, tumor activity and 285 
treatment, and reason for admission. Overall, there was no evidence for effect 286 
modification among subgroups for mortality (Figure 3). Similarly, regarding the 287 
composite endpoint of adverse outcome, no significant effect in interaction analysis 288 
was found for any subgroup (Appendix, Supplemental Figure 2).  289 
 290 












The principal findings of this secondary analysis of a large-scale, randomized, 293 
controlled nutritional trial focusing on hospitalized patients with different types of 294 
cancer are twofold. First, nutritional risk was strongly associated with mortality at 6 295 
months, which was independent of different other prognostic indicators and cancer 296 
activity. Second, compared to a control group of patients receiving standard hospital 297 
food without nutritional support, the use of individualized nutritional support to reach 298 
nutritional goals resulted in a significant improvement in mortality and other functional 299 
outcomes at short-term. These effects were consistent among different types of 300 
cancers and other predefined subgroups. 301 
 302 
Several aspects of this analysis are noteworthy. Firstly, we observed a strong 303 
increase in mortality in patients with higher nutritional risk, corroborating previous 304 
reports in this patient population. [10, 11, 28] Indeed, patients with an NRS of ≥5 305 
points had a 19% higher risk of long-term mortality compared to those with 3 points. 306 
The results remained similar when adjusting the analysis for other prognostic 307 
indicators and cancer-associated factors, suggesting that nutritional status 308 
independently predict outcome in this population of patients. Further strong 309 
associations were found between NRS and other clinically-relevant secondary 310 
outcomes. Risk screening by NRS thus allows to identify a group of cancer patients 311 
at highest risk for adverse outcome where clinical attention is indicated. 312 
 313 
Second, While the negative prognostic implications of deteriorating nutritional status 314 
in patients with cancer have previously been demonstrated, conclusive evidence 315 
regarding clinical effects of nutritional support in this population is currently scarce 316 











treatment.[6, 7, 28] Importantly, clinicians may be reluctant to provide nutritional 318 
support to patients with cancer with low appetite but rather focus on anti-cancer 319 
treatments to improve the underlying problem.[12] Herein, our data provide evidence 320 
that patients show strong benefit from nutritional support, with a greater than 5% 321 
reduction in mortality (i.e., from 19.9% to 14.1%).  Interestingly, this effect was found 322 
independent of type of cancer and cancer activity, although some of the subgroups 323 
investigated were small and do not allow firm conclusions. Clearly, the subgroup 324 
analysis was underpowered with risks for type II error. In fact, visual inspection of the 325 
forest plots suggests some numerical heterogeneities (e.g., patients with only 326 
moderate nutritional risk [NRS 3 points] and patients with cancer-associated pain as 327 
their main reasons for admission) pointing to possible lack of effect or even harm 328 
regarding adverse outcome in these subgroups. Importantly, there may be 329 
differences among cancer patients regarding the potential benefit from nutrition. For 330 
example, patients with chronic catabolism driven by cancer-related systemic 331 
inflammation may be less likely to show benefit from nutritional support. Yet, we did 332 
not collect such data in our trial for more specific phenotyping of patients and were 333 
thus not able to test this hypothesis. Clearly, prospective trials are needed with more 334 
homogenous groups of patients regarding type of cancer and treatment to 335 
understand which clinical situation provides the best opportunity for intervention.  336 
Nevertheless, our results support the clinical relevance of simultaneously addressing 337 
patients’ oncological and nutritional needs, and provide a possible explanation to the 338 
recently reported discrepancies in outcomes for patients enrolled in clinical trials and 339 
those in registries.[29] Considering that patients with cancer with comorbidities, 340 
including malnutrition, are less likely to be offered to participate to a clinical trial,[30] 341 











concurrent care may enhance patients with cancer’ quality of life, an issue frequently 343 
overlooked even under the protected umbrella of a clinical trial.[31] 344 
 345 
Third, unlike other trials investigating the effect of specific nutritional formulas,[32] we 346 
used a variety of nutritional support strategies with the support of trained dieticians to 347 
reach nutritional goals. Our trial does thus not provide evidence for effects of single 348 
nutritional components, but rather suggests that the overall strategy of providing 349 
nutritional support to reach different nutritional goals during a hospital stay for an 350 
acute illness is beneficial for patients with cancer. Because nutritional support after 351 
discharge was not standardized, and not part of the main protocol focusing on in-352 
hospital nutrition, the impact of continuing nutrition in the outpatient setting remains 353 
undefined from our data.  Clearly, there is need for additional trials validating our 354 
findings in the population of cancer patients including also continued outpatient 355 
treatment.    356 
 357 
Fourth, we also found significant improvements in functional and quality of life 358 
outcomes – a majority concern of patients with cancer [33-37]. A previous trial found 359 
no effect of nutritional intervention on quality of life and physical function in patients 360 
with cancer[38] and meta-analysis on the topic reported heterogenous results with 361 
insufficient overall evidence[39]. Again, as these previous studies focused on 362 
different populations and clinical settings, it is important to continue nutritional 363 
research in this highly vulnerable population of patients. 364 
 365 
Fifth, similar to our study, previous reports found a high prevalence of malnutrition in 366 
different types of cancer including gastrointestinal cancers (e.g., pancreatic and 367 











majority of studies focused on patients with gastrointestinal malignancies as 369 
malnutrition may appear early in these types of cancers[41] and nutrition may also 370 
improve surgical outcomes for this population[42]. As a limitation, we excluded 371 
surgical patients in our initial trial. 372 
 373 
Another important population is patients receiving antitumor treatment because 374 
treatment-related severe side-effects may lead to anorexia and weight loss.[43-46] 375 
Several studies with patients undergoing specific therapies have reported improved 376 
outcomes with nutritional support[14, 47]. One Danish trial described the association 377 
between intensive, individual dietary counseling and improved weight maintenance 378 
and higher provision of protein and energy amounts in patients with gynecologic, 379 
gastric or esophageal cancer being treated with radiotherapy and/or 380 
chemotherapy.[48, 49] These findings are in line with our report as we also had a 381 
large proportion of patients receiving antitumor therapy in the previous year.  382 
 383 
Our trial has several strengths and limitations. The main strength is that it is a 384 
secondary analysis of a prospective, randomized trial consisting of a large 385 
unselected and heterogeneous population. As a result, our patient sample represents 386 
a broad spectrum of cancer sites, treatment types and disease severities.  387 
Study limitations include the lack of blinding of participants and personnel, and some 388 
variation in the achievement of the individualized caloric and protein. We also 389 
excluded patients at end-of-life due to ethical considerations. Regarding tumor 390 
activity, we did not break down the individual antitumor therapies. Also, our control 391 
group did not receive nutritional care, including supplements, which is standard in 392 
some hospitals for patients at nutritional risk. Thus, it is not clear whether our 393 











were significant in our analysis, we did not find strong reductions in the risk for 395 
adverse outcome – a composite endpoint including severe complications, ICU 396 
admission, functional decline and rehospitalization in addition to mortality. In our 397 
main trial, we decided to focus on in-hospital nutrition only and nutritional support 398 
after discharge was not standardized, and not part of the main protocol. The impact 399 
of continuing nutrition in the outpatient setting thus remains undefined from our data.  400 
Clearly, there is need for additional trials validating our findings in the population of 401 
cancer patients including also continued outpatient treatment. Finally, as only 402 
inpatients from the medical ward were included, we have no information about 403 
patients primarily hospitalized for surgery. 404 
 405 
In conclusion, among hospitalized patients with cancer at nutritional risk, 406 
individualized nutritional support reduced the risk for mortality as compared to 407 
standard hospital food. These data support malnutrition screening upon hospital 408 
admission followed by an individualized nutritional support strategy in this vulnerable 409 
patient population. Also, they strengthen the evidence in favor of inclusion of 410 
nutritional care in the multi-professional and multidisciplinary management of patients 411 
with cancer and in relevant guidelines. 412 
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Figure 1. Kaplan-Meier estimates stratified by NRS 2002 for 180-day mortality 592 
Figure 2. Kaplan-Meier estimates of cumulative incidence of all-cause mortality 593 
within 30 days according to randomization group  594 
Figure 3. Odds ratios for mortality within 30 days in prespecified subgroups 595 
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Table 1: Patient baseline characteristicsBMI = Body Mass Index, NRS = 597 
Nutritional Risk Screening 2002; *Other hematological malignomas include essential 598 
Thrombozytopenia, Multiple Myeloma and similar illnesses; **Others include 599 
pleuramesothelioma, Cancer of unknown Primary and similar 600 
 601 
Table 2: Association of NRS score and primary and secondary outcomes. 602 
Data represent # of events (%), unless otherwise stated. All odds ratios were 603 
calculated with a logistic regression for binary data and linear regression for 604 
continuous data. Models were adjusted for patient age, sex, study center, cancer 605 
subgroups, tumor activity and treatment. Continuous values as median and IQR, 606 
categorical/binary values as absolute number and percentage. 607 
*Combined adverse outcome was a composite endpoint and includes all-cause 608 
mortality, admission to the intensive care unit from the medical ward, non-elective 609 
hospital readmission after discharge, and major complications including adjudicated 610 
nosocomial infection, respiratory failure, a major cardiovascular event (i.e., stroke, 611 
intracranial bleeding, cardiac arrest, myocardial infarction) or pulmonary embolism, 612 
acute renal failure, gastro-intestinal events (including hemorrhage, intestinal 613 
perforation, acute pancreatitis) or a decline in functional status of 10% or more from 614 
admission to day 30 measured by the Barthel’s index 615 
NRS= Nutritional Risk Screening, EQ-5D= Euroquol-5 Dimensions, VAS= Visual 616 
Analogue Scale 617 
 618 
Table 3: Effect of nutritional support on primary and secondary outcomes 619 
Data are number of events (%), unless otherwise stated. All odds ratios were 620 
calculated with a logistic regression for binary data and linear regression for 621 
continuous data. Models were adjusted for initial nutritional risk screening score and 622 
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admission to day 30 measured by the Barthel’s index 632 
NRS= Nutritional Risk Screening 2002, EQ-5D= Euroquol-5 Dimensions, VAS= 633 








Table 1: Patient baseline characteristics 
 
  Control group Intervention group 
N 251 255 
Sociodemographics     
Male sex (%) 152 (60.6%) 146 (57.3%) 
Mean age (years) (SD) 71.5 (12.4) 69.2 (13.5) 
Nutritional assessment      
Mean BMI (kg/m2) (SD) 24.8 (4.4) 24.2 (5.0) 
Mean bodyweight (kg) (SD) 72.8 (13.3) 69.7 (15.8) 
NRS 2002 score (%)     
3 points 56 (22.3%) 69 (27.1%) 
4 points 88 (35.1%) 88 (34.5%) 
5 points  87 (34.7%)  81 (31.8%) 
>5 points 20 (8.0%)  17 (6.7%) 
Tumor subgroups     
Lung cancer 49 (19.5%) 64 (25.1%) 
Gastrointestinal tumors 51 (20.3%) 33 (12.9%) 
       Colon carcinoma 15 (6.0%) 10 (3.9%) 
       Rectum carcinoma 14 (5.6%) 6 (2.4%) 
       Pancreas carcinoma 13 (5.2%) 6 (2.4%) 
       Hepatocellular carcinoma 9 (3.6%) 11 (4.3%) 
Hematological tumors 54 (21.5%) 54 (21.2%) 
       Leukemia 13 (5.2%) 18 (7.1%) 
       Lymphoma 39 (15.5%) 34 (13.3%) 
       Other hematological malignomas* 2 (0.8%) 2 (0.8%) 
Other tumors 97 (38.6%) 104 (40.8%) 
       Breast carcinoma 19 (7.6%) 17 (6.7%) 
       Prostate carcinoma 16 (6.4%) 20 (7.8%) 
       Gynecological cancers 12 (4.8%) 14 (5.5%) 
       Kidney and urothelial cancers 14 (5.6%) 12 (4.7%) 
       Ear, nose, throat  Carcinoma 4 (1.6%) 6 (2.4%) 
       Genital cancer 4 (1.6%) 3 (1.2%) 
       Skin cancer 5 (2.0%) 1 (0.4%) 
       Others** 23 (9.2%) 31 (12.2%) 
Tumor activity and treatment     
Inactive 35 (13.9%) 23 (9.0%) 
Active 216 (86.1%) 232 (91.0%) 
Reason for admission     
Cancer associated failure to thrive 58 (23.1%) 62 (24.3%) 
Cancer associated pain 36 (14.3%) 30 (11.8%) 
Cancer associated fever and infection 36 (14.3%) 31 (12.2%) 
Cancer treatment and other indications  66 (26.3%) 80 (31.4%) 









BMI = Body Mass Index, NRS = Nutritional Risk Screening 2002; *Other 
hematological malignomas include essential Thrombozytopenia, Multiple Myeloma 
and similar illnesses; **Others include pleuramesothelioma, Cancer of unknown 









Table 2: Association of NRS score and primary and secondary outcomes. 
 











Regression analysis per point 
increase in NRS 
(unadjusted) 
(95% CI und p-value) 
Regression analysis per point 
increase in NRS 
(adjusted) 
(95% CI and p-value) 
Primary outcome       
All-cause mortality within 30 days 15 (12.0%) 31 (17.6%) 40 (19.5%) HR 1.27 (0.96 to 1.67), p=0.093 1.20 (0.91 to 1.60), p=0.199 
Secondary outcomes       
All-cause mortality within 180 days 47 (37.6%) 80 (45.5%) 116 (56.6%) HR 1.33 (1.17 to 1.56), p=0.001 1.37 (1.15 to 1.61), p=0.0001 
*Combined adverse outcome within 
30 days 
32 (25.6%) 64 (36.4%) 83 (40.5%) OR 1.38 (1.09 to 1.74), p=0.008 1.42 (1.11 to 1.83), p=0.006 
Additional hospital outcome 
 
      
Admission to an intensive care unit 
within 30 days 
3 (2.4%) 6 (3.4%) 1 (0.5%) OR 0.56 (0.25 to 1.25), p=0.159 0.53 (0.21 to 1.34), p=0.180 
Non-elective hospital readmission 
within 30 days 
11 (8.8%) 16 (9.1%) 26 (12.7%) HR 1.23 (0.87 to 1.75), p=0.245 1.29 (0.90 to 1.86), p=0.162 
Mean length of index hospital stay 
(days) 
9.0 (6.8) 10.7 (7.4) 11.0 (7.5) coefficient 0.91 (0.11 to 1.72), p=0.027 1.04 (0.22 to 1.87), p=0.013 
Functional outcome 
 
      
Decline in functional status of ≥ 10% 
from admission to day 30 
17 (13.6%) 40 (22.7%) 55 (26.8%) OR 1.47 (1.11 to 1.94), p=0.006 1.50 (1.12 to 2.01), p=0.006 






Coefficient -1.11 (-2.26 to 0.04), p=0.058 -1.53 (-2.69 to -0.36), p=0.010 
Mean EQ-5D Index at day 30 (points) 0.72 (0.35) 0.65 (0.39) 0.60 (0.39) Coefficient -0.06 (0.1 to -0.02), p=0.008 -0.06 (-0.10 to -0.02), p=0.009 
Mean EQ-5D VAS at day 30 (points) 51 (28) 45 (30) 42 (31) Coefficient -4.74 (-8.36 to -1.13), p=0.01 -4.18 (-7.88 to -0.47), p=0.027 
 
Data represent # of events (%), unless otherwise stated. All odds ratios were calculated with a logistic regression for binary data and linear regression for 
continuous data. Models were adjusted for patient age, sex, study center, cancer subgroups, tumor activity and treatment. Continuous values as median and 
IQR, categorical/binary values as absolute number and percentage. 
*Combined adverse outcome was a composite endpoint and includes all-cause mortality, admission to the intensive care unit from the medical ward, non-elective 
hospital readmission after discharge, and major complications including adjudicated nosocomial infection, respiratory failure, a major cardiovascular event (i.e., 
stroke, intracranial bleeding, cardiac arrest, myocardial infarction) or pulmonary embolism, acute renal failure, gastro-intestinal events (including hemorrhage, 
intestinal perforation, acute pancreatitis) or a decline in functional status of 10% or more from admission to day 30 measured by the Barthel’s index 



















(95% CI and p-value) 
Primary outcome     
All-cause mortality within 30 days 50 (19.9%) 36 (14.1%) OR 0.57 (0.35 to 0.94), p=0.027 
Secondary outcomes     
Clinical outcome     
Combined adverse outcome within 30 days 93 (37.1%) 86 (33.7%) OR 0.81 (0.56 to 1.19), p=0.288 
Additional hospital outcomes     
Admission to an intensive care unit within 30 days 6 (2.4%) 4 (1.6%) OR 0.62 (0.16 to 2.5), p=0.503 
Non-elective hospital readmission within 30 days 22 (8.8%) 31 (12.2%) OR 1.53 (0.85 to 2.75), p=0.159 
Mean length of stay stay of index hospital stay (days) 10.4 (6.9) 10.4 (7.8) HR 1.14 (0.93 to 1.40), p=0.206 
Functional outcome     
Decline in functional status of ≥ 10% from admission to 
day 30 
67 (26.7%) 45 (17.6%) OR 0.59 (0.38 to 0.93), p=0.021 
Mean Barthel Index score at day 30 (points) 94.72 (10.68) 94.98 (10.21) Coefficient 0.6 (-1.16 to 2.36), p=0.506 
Mean EQ-5D Index at day 30 (points) 0.62 (0.39) 0.67 (0.37) Coefficient 0.08 (0.01 to 0.15), p=0.016 
Mean EQ-5D VAS at day 30 (points) 43 (30) 48 (29) Coefficient 6.16 (0.51 to 11.8), p=0.033 
Long-term mortality     
All-cause mortality within 180 days 128 (52.7%) 115 (47.3%) HR 0.83 (0.65 to 1.08), p=0.18 
 
Data are number of events (%), unless otherwise stated. All odds ratios were calculated with a logistic regression for binary data and linear regression for 
continuous data. Models were adjusted for initial nutritional risk screening score and study center. Continuous values as median and IQR, categorical/binary 
values as absolute number and percentage. 
*Combined adverse outcome was a composite endpoint and includes all-cause mortality, admission to the intensive care unit from the medical ward, non-elective 
hospital readmission after discharge, and major complications including adjudicated nosocomial infection, respiratory failure, a major cardiovascular event (i.e., 
stroke, intracranial bleeding, cardiac arrest, myocardial infarction) or pulmonary embolism, acute renal failure, gastro-intestinal events (including hemorrhage, 
intestinal perforation, acute pancreatitis) or a decline in functional status of 10% or more from admission to day 30 measured by the Barthel’s index 
NRS= Nutritional Risk Screening 2002, EQ-5D= Euroquol-5 Dimensions, VAS= Visual Analogue Scale 
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